Defence Therapeutics, Inc. engages in the research and development of anti-body drug conjugates. It focuses on enhancing intracellular delivery of biological or biosimilar therapeutic drugs targeting cancer and infectious diseases. The company was founded by Simon Beaudoin and Sébastien Plouffe on July 18, 2017 and is headquartered in Vancouver, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company